---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-066317"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2026-05-26T20:42:33+00:00"
generated_at: "2026-05-26T20:46:32.763929+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Editas Medicine prices $125M public offering of shares and warrants

## Summary
- Priced 55,555,556 shares and warrants at $2.25 per unit; gross proceeds $125M before warrant exercise.
- Warrants exercisable at $3.50/share, expire upon EDIT-401 Phase 1 data milestone or within 3 years.
- If all warrants exercised, additional proceeds ~$194.4M; net proceeds estimated ~$117M.
- Cash runway extended into second half of 2028 based on current plans.
- Underwriters: Cantor Fitzgerald and Wells Fargo; closing expected May 27, 2026.

## SEC filing metadata
- accession: 0001104659-26-066317
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2026-05-26T20:42:33+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000110465926066317/0001104659-26-066317-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000110465926066317/tm2615565d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-066317
- JSON: https://secwatch.observer/filing/0001104659-26-066317.json
- Plain text: https://secwatch.observer/filing/0001104659-26-066317.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.